524731
Jenburkt Pharma financials
- Market cap
- ₹443 Cr
- Sector
- Healthcare
What Jenburkt Pharma does
Jenburkt Pharmaceuticals Limited is an Indian pharmaceutical company listed on the BSE under script code 524731. The documents available in this bundle are limited to the FY2024-25 AGM notice, e-voting instructions, and shareholder compliance procedures, and do not describe the company's manufacturing operations, plants, product portfolio, or business segments.
Quarterly results
Q1 FY27: revenue down 0.1%, net profit down 24.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 37 | 41 | 36 | 46 +11% | 43 +17% | 45 +9% | 36 −0% |
| EBITDA | 11 | 9 | 11 | 9 | 13 +15% | 7 −16% | 14 +31% | 6 −33% |
| Net profit | 10 | 7 | 9 | 8 | 10 +6% | 6 −9% | 11 +27% | 6 −24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −7.8% 1Y
1Y: ₹1,092.1 on 10 Sept 2025 → ₹1,006.7. High ₹1,275.85 (3 Nov 2025), low ₹955.45 (30 Mar 2026).
Financials, as filed
Revenue grew 7.3% a year over 3 years, FY23 to FY26. Operating margin widened to 25.9%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹137 Cr | ₹142 Cr | ₹152 Cr | ₹169 Cr |
| Operating profit | ₹30 Cr | ₹33 Cr | ₹40 Cr | ₹44 Cr |
| Operating margin | 22.1% | 23.3% | 26.6% | 25.9% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr |
| Net profit | ₹24 Cr | ₹26 Cr | ₹32 Cr | ₹35 Cr |
| Net margin | 17.8% | 18.3% | 21.1% | 20.6% |
| Cash from operations | ₹17 Cr | ₹8 Cr | ₹28 Cr | ₹27 Cr |
| Free cash flow | ₹15 Cr | ₹6 Cr | ₹8 Cr | ₹13 Cr |
| ROCE | 27.0% | 26.0% | 27.0% | 27.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Reserves | ₹94 Cr | ₹113 Cr | ₹118 Cr | ₹141 Cr | ₹178 Cr | ₹193 Cr |
| Borrowings | ₹5 Cr | ₹7 Cr | ₹3 Cr | ₹0 Cr | ₹2 Cr | ₹2 Cr |
| Other liabilities | ₹17 Cr | ₹18 Cr | ₹16 Cr | ₹19 Cr | ₹24 Cr | ₹26 Cr |
| Total liabilities | ₹120 Cr | ₹143 Cr | ₹141 Cr | ₹164 Cr | ₹209 Cr | ₹225 Cr |
| Fixed assets | ₹11 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹14 Cr | ₹19 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹52 Cr | ₹46 Cr |
| Investments | ₹7 Cr | ₹8 Cr | ₹11 Cr | ₹17 Cr | ₹27 Cr | ₹27 Cr |
| Other assets | ₹103 Cr | ₹123 Cr | ₹119 Cr | ₹136 Cr | ₹116 Cr | ₹132 Cr |
| Total assets | ₹120 Cr | ₹143 Cr | ₹141 Cr | ₹164 Cr | ₹209 Cr | ₹225 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count grew 6% to 7,103.
- Promoters
- 46.6%
- DIIs
- 0.1%
- Public
- 53.3%
Since Jun 2025
- Public +0.06 pp
- Promoters −0.05 pp
- FIIs 0.00 pp
How it drifted, 12 quarters
Over this window the public went from 51.2% to 53.3% — +2.1 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 47.4%, FIIs 1.4%, Public 51.2%.Dec '23: Promoters 47.4%, Public 52.6%.Mar '24: Promoters 47.2%, Public 52.8%.Jun '24: Promoters 46.7%, Public 53.3%.Sep '24: Promoters 46.7%, Public 53.3%.Dec '24: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Mar '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Jun '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Sep '25: Promoters 46.7%, DIIs 0.1%, Public 53.2%.Dec '25: Promoters 46.6%, DIIs 0.1%, Public 53.2%.Mar '26: Promoters 46.6%, DIIs 0.1%, Public 53.2%.Jun '26: Promoters 46.6%, DIIs 0.1%, Public 53.3%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Optirational Ventures Llp newly disclosed 1.20% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Jenburkt Pharma above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ashish Uttam Bhuta | 18.07% | unchanged |
| Bhuta Holdings Private Limited | 13.96% | unchanged |
| Kalindi Hemendra Bhuta | 9.06% | unchanged |
| Nirmala Vinodkumar Daga | 3.30% | unchanged |
| Investor Education And Protection Fund Authority | 2.32% | unchanged |
| Ranjeet Singh Sibia | 1.50% | unchanged |
| Optirational Ventures Llp | 1.20% | newly disclosed |
| Bhavika Ashish Bhuta | 1.17% | unchanged |
| Kunti Ketan Gala | 1.16% | unchanged |
| Rajiv Garg | 1.07% | unchanged |
| Parshva Kumar Daga | 1.05% | unchanged |
| Sushila Paraskumar Daga | 1.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹1007, this stock must grow earnings at 5% every year for 7 years. Our analysis caps realistic growth at ~13%. At that growth it is worth ₹1600 — upside of 59%.
- Growth the price implies
- 4.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.5% a year
- net profit, FY23–FY26 · EPS 13.3%
- The gap
- -0.1 pp
- 59% downside if it only repeats history
Learn to analyse Jenburkt Pharma
Guides on how to read this kind of business and the numbers that matter.